BRAF and metastatic melanoma: The same schedule was also confirmed as the MTD in the expansion part of the study, enrolling patients with both BRAF-mutated and BRAF-WT metastatic melanoma, with the infusion time increased to 60 min to reduce the potential for QTc prolongation.